Veracyte Stock Cash Flow From Operations
| VCYT Stock | USD 31.47 0.34 1.09% |
Veracyte's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Veracyte Stock price.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Veracyte Company Cash Flow From Operations Analysis
Veracyte's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Veracyte Cash Flow From Operations | 75.1 M |
Most of Veracyte's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Veracyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Veracyte has 75.1 M in Cash Flow From Operations. This is 85.76% lower than that of the Biotechnology sector and 20.11% higher than that of the Health Care industry. The cash flow from operations for all United States stocks is 92.27% higher than that of the company.
Veracyte Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Veracyte's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Veracyte could also be used in its relative valuation, which is a method of valuing Veracyte by comparing valuation metrics of similar companies.Veracyte is currently under evaluation in cash flow from operations category among its peers.
Veracyte Fundamentals
| Return On Equity | 0.0218 | ||||
| Return On Asset | 0.0139 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 2.15 B | ||||
| Shares Outstanding | 77.94 M | ||||
| Shares Owned By Insiders | 0.66 % | ||||
| Shares Owned By Institutions | 99.34 % | ||||
| Number Of Shares Shorted | 4.17 M | ||||
| Price To Earning | (10.61) X | ||||
| Price To Book | 2.03 X | ||||
| Price To Sales | 5.54 X | ||||
| Revenue | 445.76 M | ||||
| Gross Profit | 309.7 M | ||||
| EBITDA | 49.2 M | ||||
| Net Income | 24.14 M | ||||
| Cash And Equivalents | 170.11 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 50.74 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.09 X | ||||
| Book Value Per Share | 15.12 X | ||||
| Cash Flow From Operations | 75.1 M | ||||
| Short Ratio | 4.17 X | ||||
| Earnings Per Share | 0.31 X | ||||
| Target Price | 42.2 | ||||
| Number Of Employees | 824 | ||||
| Beta | 2.04 | ||||
| Market Capitalization | 2.47 B | ||||
| Total Asset | 1.3 B | ||||
| Retained Earnings | (443.98 M) | ||||
| Working Capital | 293.63 M | ||||
| Current Asset | 47.91 M | ||||
| Current Liabilities | 14.72 M | ||||
| Net Asset | 1.3 B |
About Veracyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Veracyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Veracyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Veracyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.